COBALT

COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT)

Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are related conditions with a wide range of distressing symptoms. Acetylcholinesterase Inhibitor (AChEI) are commonly used medicines that can help people with DLB/PDD by improving day to day functioning and thinking abilities. Another drug which might help is Memantine which may help to improve cognition, awareness and the ability to perform daily functions. However, it is not clear if adding Memantine to AChEI is beneficial for people with DLB/PDD.

COBALT is an international, multi-centre, parallel arm, double blind, randomised placebo-controlled trial to assess the clinical and cost-effectiveness of memantine in patients with dementia with Lewy bodies (DLB) and patients with Parkinson’s disease dementia (PDD) already taking an acetylcholinesterase inhibitor (AChEI; donepezil, rivastigmine or galantamine). It is being performed as two separate trials (COBALT-DLB and COBALT-PDD)